Dottikon ES Holding AG Logo

Dottikon ES Holding AG

Exclusive synthesis of APIs & fine chemicals via hazardous reactions for pharma/biotech industries.

DESN | SW

Overview

Corporate Details

ISIN(s):
CH0582581713
LEI:
50670064H782SV8G2Z44
Country:
Switzerland
Address:
Hembrunnstrasse 17, 5605 Dottikon
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dottikon ES Holding AG specializes in the exclusive synthesis of fine chemicals, manufacturing high-quality performance chemicals, intermediates, and active pharmaceutical ingredients (APIs). Serving the global chemical, biotech, and pharmaceutical industries, the company's core expertise lies in hazardous reactions, leveraging over 110 years of experience. Dottikon provides comprehensive services from research and development, including route-finding and process development, to multi-ton cGMP-compliant production. All operations are managed from a single strategic site, with quality management systems approved by the FDA and Swissmedic.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dottikon ES Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Dottikon ES Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-18 N/A Executive member Sell None 19,500,000.00 CHF
2023-07-24 N/A Executive member Sell None 72,600.00 CHF
2023-06-15 N/A Executive member Sell None 85,872,280.00 CHF
2023-06-15 N/A Non-Executive member Buy None 26,000.00 CHF
2023-06-01 N/A Non-Executive member Buy None 30,240.00 CHF

Peer Companies

Company Country Ticker View
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland GALD

Talk to a Data Expert

Have a question? We'll get back to you promptly.